Hospital stocks extend losses after SC questions cancer drug markups
In short
Hospital stocks fell again for a second session after the Supreme Court questioned steep markups on cancer drugs. The court also flagged hospitals forcing patients to buy medicines from their own or chosen pharmacies.
This matters because it could affect hospital pricing and pharmacy practices. The report does not say whether any rule has changed yet.
What the reporting says
Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs, according to Economic Times summaries. The court also raised concerns about hospitals requiring patients to buy medicines from their own or designated pharmacies. The immediate consequence was fresh selling in hospital stocks, but the report does not state which companies fell most or whether any policy action followed.
Why it matters
Hospital stocks continued to slide after the Supreme Court questioned steep markups on cancer drugs and raised concerns about hospitals directing patients to their own or designated pharmacies. The summary does not mention any specific hospital company moves or any formal order from the court. The development put pressure on the hospital sector and raised uncertainty over pricing and pharmacy practices.